HZX-02-059

News alerts, weekly reports and conference planners

Company:

Xiamen University

Drug class:

Tubulin inhibitor, PIKfyve inhibitor

Related drugs:

MYC rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL6 rearrangement	Lymphoma	HZX-02-059 Sensitive: D – Preclinical HZX-02-059 Sensitive : D	HZX-02-059 Sensitive: D – Preclinical HZX-02-059 Sensitive : D
MYC rearrangement + BCL2 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement	Lymphoma	HZX-02-059 Sensitive: D – Preclinical HZX-02-059 Sensitive : D	HZX-02-059 Sensitive: D – Preclinical HZX-02-059 Sensitive : D

Associations
(2)